Login / Signup

Switching from Infliximab Originator to SB2 Biosimilar in Inflammatory Bowel Diseases: A Multicentric Prospective Real-Life Study.

Davide MassimiBrigida BarberioLorenzo BertaniFrancesco CostaAntonio FerronatoSonia FacchinRomilda CardinLinda CingolaniCesare CasadeiRenata D'IncàFabiana ZingoneEdoardo Vincenzo Savarino
Published in: Therapeutic advances in gastroenterology (2021)
Overall, our data show that most of the patients switching from Infliximab originator to SB2 maintain the clinical and biochemical remission for at least 1 year. Further data are necessary to understand the clinical implications of these findings in the long term.
Keyphrases
  • end stage renal disease
  • ulcerative colitis
  • electronic health record
  • ejection fraction
  • chronic kidney disease
  • big data
  • peritoneal dialysis
  • prognostic factors
  • rheumatoid arthritis